Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 212Pb-PSV359 |
| Synonyms | |
| Therapy Description |
212Pb-PSV359 is a radioconjugate comprising a FAP-binding cyclic peptide linked to the radionuclide 212Pb, which potentially inhibits growth of FAP-expressing tumors (J Nucl Med June 2024, 65 (supplement 2) 241158). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 212Pb-PSV359 | [212Pb]PSV359|212PbPSV359 | 212Pb-PSV359 is a radioconjugate comprising a FAP-binding cyclic peptide linked to the radionuclide 212Pb, which potentially inhibits growth of FAP-expressing tumors (J Nucl Med June 2024, 65 (supplement 2) 241158). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06710756 | Phase Ib/II | 212Pb-PSV359 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | Recruiting | USA | 0 |